Knopp Neurosciences Inc. ("Knopp") said it initiated the first Phase 2 study of KNS-760704 in patients with amyotrophic lateral sclerosis (ALS).

Knopp Neurosciences Inc. ("Knopp") said it completed a Series B funding round of $10 million, increasing its total capitalization to $20 million. The latest financing involved the exercise of milestone-based callable warrants held by existing investors in Knopp.

Knopp Neurosciences Inc. ("Knopp") presented results of its ascending single-dose study of KNS-760704, an orally bioavailable small molecule therapy in development for amyotrophic lateral sclerosis (ALS), at the 18th International Symposium on ALS/MND in Toronto.

PITTSBURGH, Oct. 3 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") announced that Cheryl Fossum Graham, M.D., F.C.P., has joined the company as senior vice president of regulatory and development strategy. (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) Dr.

PITTSBURGH, Sept. 24 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") today announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of amyotrophic lateral sclerosis (ALS).